AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06163833 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-storage solution
Description: Placebo has to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI. It has to be diluted 1:2 in a saline solution for a total of 36mL.
Study NCT05871879 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The 5-item modified frailty index
Description: The mFI-5 contains five items, including hypertension, diabetes, congestive heart failure (CHF), chronic obstructive lung disease (COPD), and physical function status, with each item attributing 1 point. Patients with an mFI-5 score greater than or equal to 2 were considered frail, while those with an mFI-5 score of 0 or 1 were considered nonfrail.
Study NCT04636749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erbium laser
Description: Vaginal laser therapy
Study NCT04636749 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: Sham laser therapy
Study NCT05021627 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac autonomic nerve modification
Description: Patients with sinus bradycardia undergoing cardiac autonomic ganglion ablation. Specific anatomic ablation of the 4 major left atrial GP and aorta-superior vena cava (Ao-SVC) GP was performed. Briefly, catheter ablation was performed under the guidance of an electroanatomic mapping system (CARTO,BiosenseWebster,DiamondBar,California). After completed the electroanatomic mapping of the left atrium was complete and pulmonary vein (PV) ostia identified, presumed GP clusters were ablated 1 to 2cm outside the PV-left atrium junctions at the following sites: the left superolateral area (leftsuperior GP\[LSGP\]), the leftinfer oposterior area(left inferior GP\[LIGP\]), the right superoanterior area (rightanterior GP\[RAGP\]), the right inferoposterior area(right inferior GP\[RIGP\]), and the Ao-SVC fat pad (Ao-SVCGP), and in that sequence.
Study NCT05021627 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation
Description: Patients with sinus bradycardia received pacemaker implantation. The patient lay flat on the bed, puncture the subclavian vein and insert two guide wires. Cut the skin under the guide wire to make a skin bag, and stop bleeding accurately to avoid continuous bleeding of the skin bag. The pacemaker electrode is inserted into the heart cavity by guiding the guide wire, one is placed in the ventricle and the other in the atrium, and the corresponding parameters of the electrode, such as pacing threshold, impedance, etc., are measured at the same time. If the parameters are good, fix the electrode, connect the electrode with the pacemaker, place the pacemaker in the skin bag, fix the pacemaker and electrode, suture the skin layer by layer, and the operation is completed.
Study NCT05515809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parasternal block
Description: Echo-guided loco-regional anesthesia by bilateral parasternal block in immediate preoperative.~The drug used is Ropivacaine 2mg/ml, 0.2%. Injection of 20ml per side, under ultrasound control, after general anaesthesia and before skin incision, and therefore before surgery
Study NCT05515809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard pain management
Description: Standard pain management care involves a multimodal strategy that includes the use of intravenous analgesics. Morphine medications are the mainstay of pain management
Study NCT04552756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Seizure Diary
Description: The patients keep a seizure diary during the period of radiotherapy and up to 6 weeks following radiotherapy. Every day, the patients document the number (and type) of seizures and intake of anti-epileptic medication. The seizure diary will be used to assess the rate of patients with progression of seizure events during the course of radiotherapy compared to baseline.~To obtain an objective assessment of seizure activity in addition to patient reported outcomes, an electroencephalography (EEG) is performed during the first and the sixth week of radiotherapy, as well as during the sixth week following radiotherapy. Activity typical for epilepsy includes spike waves, sharp waves and/or sharp slow waves and is classified as absent or present.
Study NCT04760847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: These subjects will will then receive information regarding intermittent fasting, which would include fasting for a 16-hour period each day, followed by ingestion of an appropriate number of calories for the remaining part of the day. See attached IF Quick Facts for details provided to the patient.
Study NCT04760847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intermittent fasting
Description: These subjects will undergo standard caloric dietary guidance. Patients in group B will also be given the above information, though not be asked to intermittently fast
Study NCT05714891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: Dose will be assigned at enrollment
Study NCT05695183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IV SafeLock
Description: Designed to prevent patient access to intravenous lines in the hospital setting. The device locks with an institution specific key and protects the hub as well as all tubing access points.
Study NCT06534151 — intervention group
Intervention type: DEVICE
Intervention: CRT implantation
Description: A CRT is a device (that looks like a pacemaker) that will be used to help the ventricles contract synchronously.
Study NCT05018611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeSkills Mobile
Description: A mobile app designed to facilitate the broad reach and impact of the LifeSkills intervention to reduce sexual risk behavior which drives HIV infection. The LifeSkills intervention addresses the specific structural, developmental, and interpersonal challenges to HIV prevention among YTW ages 16-29, with prior evidence of the efficacy to reduce sexual risk.
Study NCT05566301 — intervention group
Intervention type: DRUG
Intervention: Clopidogrel
Description: All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel
Study NCT05566301 — intervention group
Intervention type: DRUG
Intervention: Ticagrelor
Description: All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel
Study NCT05406687 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health Navigator Model
Description: The Health Navigator Model will be a longitudinal, person-centered and community-based intervention focused on addressing both primary and secondary cancer prevention, as well as reducing wider barriers to healthcare. Health Navigators (HNs) will be professionals who have a background in social care and an understanding of the local user population, and will be embedded in settings familiar and accessible to people experiencing homelessness. The primary aspects of the HN role will be to identify the health needs and barriers of users, promote cancer awareness and education, facilitate timely access to healthcare services and cancer screening, provide practical assistance, delivered through regular in-person meetings, and utilize wider stakeholders, including healthcare professionals, to deliver the intervention. A comprehensive training package will be delivered to the HNs, covering population specific knowledge, interpersonal skills, cancer education and local resources.
Study NCT06291922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: See arm description.
Study NCT06291922 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: See arm description.
Study NCT05233228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.
Study NCT05233228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.
Study NCT05233228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help materials (to support smoking cessation)
Description: The self-help materials were developed by NTCC in Lao, based on the World Health Organization's A guide for tobacco users to quit.
Study NCT05233228 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help materials (to support smoking cessation)
Description: The self-help materials were developed by NTCC in Lao, based on the World Health Organization's A guide for tobacco users to quit.
Study NCT05233228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-based automated treatment for smoking cessation
Description: The automated treatment(AT) include text messages, images, and videos. The AT content is designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The AT will begin immediately after enrollment and continue for a 26-week period. The AT approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.
Study NCT05697822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Phone and Cloud-based Electronic Contact and Recording System
Description: A mobile phone application has been developed which is intended to be used by pregnant women and their healthcare workers. A pregnant woman can get registered in this app and enter information and data related to their health and current pregnancy. Their health worker at their health post can access this information on their mobile phone too. The pregnant woman can also input her daily symptom on this app. She can also input and/or access information on examination and tests that have been carried out. If a concerning symptom or event has been entered by a user in the app, the health worker will be notified through this app. The health worker can also track the pregnant women under their care through this application. A cloud-based database of pregnant women will have the details of all the pregnant women in a given ward or rural municipality. Health coordinators in the municipality will be able to access the database for their municipality and track the pregnant women, if needed.
Study NCT04301609 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active
Description: Take 4 capsules daily (2 capsules on an empty stomach + 2 capsules 30 minutes before dinner).
Study NCT04301609 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 4 capsules daily (2 capsules on an empty stomach + 2 capsules 30 minutes before dinner).
Study NCT06270901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Planetary Health Diet
Description: Planetary Health Diet Meal with 62 g of protein primarily from plant origin
Study NCT06270901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Protein Planetary Health Diet
Description: Planetary Health Diet Meal with 36 g of protein primarily from plant origin
Study NCT06270901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Western Diet
Description: Western Diet Meal with 62 g of protein primarily from animal origin
Study NCT06270901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Protein Western Diet
Description: Western Diet Meal with 36 g of protein primarily from animal origin
Study NCT05827068 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1011.1
Description: Sterile liquid for injection
Study NCT05827068 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1011.2
Description: Sterile liquid for injection
Study NCT05827068 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1012.1
Description: Sterile liquid for injection
Study NCT05827068 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1010
Description: Sterile liquid for injection
Study NCT05827068 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1010.2
Description: Sterile liquid for injection
Study NCT05827068 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1010.3
Description: Sterile liquid for injection
Study NCT06453980 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Participants will receive sham (placebo) HD-tDCS for 20 minutes, for 1 session.
Study NCT06453980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Participants will receive HD-tDCS at 3 milliAmp for 20 minutes, for 1 session.
Study NCT05568992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI system of optical detection of advanced adenomas
Description: AI system of optical detection of advanced adenomas
Study NCT04182490 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LMN-101
Description: VHH-derived binding protein designed to bind and inhibit FlaA, flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, spirulina biomass
Study NCT04182490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical appearing placebo
Study NCT06465849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dentin Etching time for 5 seconds
Description: Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on dentin etched for 5 seconds in the etch-and-rinse application strategy.
Study NCT06465849 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scotchbond Universal Plus; 3M
Description: Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive (Scotchbond Universal Plus; 3M).
Study NCT06465849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal Plus; 3M
Description: Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive (Scotchbond Universal Plus; 3M).
Study NCT06465849 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gluma Universal Bond; Kulzer
Description: Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive (Gluma Universal Bond; Kulzer).
Study NCT06465849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gluma Universal Bond; Kulzer
Description: Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive (Gluma Universal Bond; Kulzer).
Study NCT06465849 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dentin Etching time for 15 seconds
Description: Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on dentin etched for 15 seconds in the etch-and-rinse application strategy.
Study NCT05797285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: human keratin graft
Description: The intervention to be applied is an advanced wound care matrix composed of human keratin to be applied at two different treatment frequencies.
Study NCT06255223 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-dose Radiotherapy (HDRT)
Description: SBRT was adopted, and radiotherapy plan was made according to the location and size of lesions (total dose 20-70Gy, 5-12Gy every time).
Study NCT06255223 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose Radiotherapy (LDRT)
Description: Radiotherapy plan was made according to the location and size of lesions (total dose 2Gy, 1Gy every time). After completing SBRT, LDRT was performed on as many metastatic sites as possible.
Study NCT06255223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: At the end of multimodal radiotherapy, immunotherapy was given within 7 days and in a subsequent LDRT. The maximum duration is 24 months.
Study NCT05947877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-pharmacological pain management strategies
Description: Non-pharmacological pain management strategies
Study NCT05928598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey questionnaires
Description: Participants will be enrolled before a scheduled clinic appointment. Following the clinic visit, the research staff will ask the patient to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record.
Study NCT05928598 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Survey questionnaires
Description: Participants will be enrolled before a scheduled clinic appointment. Following the clinic visit, the research staff will ask the patient to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record.
Study NCT05928598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Epilepsy Visit Planner
Description: Participants will be identified before a scheduled clinic appointment. Prior to the clinic visit (at the site) the participants will meet with a research staff to obtain written informed consent and then present the Epilepsy Visit Planner to the patient. Participants will be encouraged to use the Planner and share the Planner's output with the provider during the clinic visit. In some cases, there could be an option for the participants to consent prior to the visit and have a virtual presentation of the Planner.~Following the clinic visit, the research staff will ask the participants to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record.
Study NCT05928598 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires for Providers
Description: Providers will be asked to complete a survey after the clinic visit for the intervention group.
Study NCT05371184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Glutamine, Oral Powder for Reconstitution
Description: Glutamine is an essential amino acid. It will be provided in a powder form. It will be dissolved in at least 8 ounces of hot or cold liquid. It can also be mixed with a soft food such as pudding, applesauce, or yogurt. Then it will be Stirred and then eaten or drunken The Glutamine will be as an add on to the Standard of care
Study NCT05371184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Hydroxyurea 15-25 mg per kg per day and/ or blood transfusion therapy
Study NCT02856932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional high viscosity glass ionomer
Description: Dental restorative material
Study NCT02856932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glass ionomer with glass hybrid technology
Description: Dental restorative material
Study NCT06120426 — intervention group
Intervention type: PROCEDURE
Intervention: total en bloc spondylectomy
Description: Total enbloc resection (TES) is one of the most challenging surgeries in spinal surgery and a classic surgical method. It not only relieve spinal cord compression and delays tumor recurrence, but also prolongs patient survival, significantly reduces hand surgery trauma, and improves surgical safety. However, for cases with extensive tumor invasion, methods such as separation surgery should be used to relieve spinal cord nerve compression, rebuild spinal stability, and provide conditions for postoperative radiotherapy.
Study NCT05679739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized blood pressure strategy
Description: An individualized blood pressure strategy targeting cerebral blood flow, serially guided by near-infrared spectroscopy and transcranial Doppler ultrasound. Assessments are performed on admission, and at 12, 24 and 48 hours post-ROSC.
Study NCT04861727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRPA procedure
Description: The patient will receive the device for BP measurement at home for a week and two daily measurements will be taken, one in the morning (between 6 and 10 am) and one in the afternoon / evening (between 6 pm and 10 pm), for seven days. At the end of the procedure, it is expected to record 14 measurements (representing a total of 42 in seven days), but it is considered feasible when at least 10 results are recorded, respecting the number of two measurements per day, in the periods oriented. Participants who do not reach the satisfactory number of measures or do not check between the times mentioned above, will be invited to repeat the procedure